Abstract:BACKGROUND:To search for genes with high sensitivity and to explore its application value related to clinical prognostic prediction, so as to provide important foundation for the preventive intervention, early diagnosis, treatment and prognosis evaluation for breast cancer.METHODS:Tissue samples from ten clinical breast cancer patients were collected to search for the common mutant genes among various samples, and to explore the enrichment degree of mutant genes at both disease and signaling pathway levels using the whole exome sequencing (WES). Subsequently, targets genes with changes in expression levels that showed high correlations with mutation were screened from the above common genes using The Cancer Genome Atlas (TCGA) database. On this basis, differences in the mutation and expression levels of the screened target genes between breast cancer tissues and para-carcinoma tissues, as well as their correlations with patient survival were analyzed using the gene expression and mutation data in TCGA database, together with the clinical information. Finally, the potential regulatory pathways and potential downstream targets of the target genes were predicted through gene set enrichment analysis (GSEA) using Multi-Experiment Matrix (MEM) software.RESULTS:A total of 23 common mutant genes were discovered from the tissue samples from ten breast cancer patients, which were mostly enriched in the cancer, PI3K/Akt and cAMP signaling pathways. Among these 23 genes, only the changes in the expression levels of ZNF384 and PDE4DIP had displayed over 15% consistency with mutation. Besides, it was discovered through TCGA database analysis that, the expression level of ZNF384 gene in breast cancer tissues with ZNF384 mutation was far higher than that in those with no ZNF384 mutation. Moreover, such gene mutation and high expression had shown significantly positive correlation with the patient survival (P<0.05). In addition, GSEA indicated that, tissues with high ZNF384 expression were associated with enrichments related to cell cycle signaling pathway and mitosis metaphase pathway, while this series of effects might be correlated with its regulation on the level and activity of its downstream gene CXCL14.CONCLUSIONS:ZNF384 mutation and up-regulated ZNF384 expression level in breast cancer tissues is significantly positively correlated with patient survival. Therefore, ZNF384 can serve as a molecular marker for the diagnosis and prognostic prediction of breast cancer as well as a potential therapeutic target.

ZNF326 promotes a malignant phenotype of breast cancer by interacting with DBC1

ZNF276 promotes the malignant phenotype of breast carcinoma by activating the CYP1B1-mediated Wnt/β-catenin pathway

ZNF326 Promotes Colorectal Cancer Epithelial-Mesenchymal Transition

Overexpression and Mutation of ZNF384 is Associated with Favorable Prognosis in Breast Cancer Patients.

Zinc Finger Protein 593 Promotes Breast Cancer Development by Ensuring DNA Damage Repair and Cell Cycle Progression

ZNF623 contributes to breast carcinoma progress by recruiting CtBP1 to regulate NF-κB pathway

Zinc finger protein 367 promotes metastasis by inhibiting the Hippo pathway in breast cancer

Disruption of ZNF334 Promotes Triple-Negative Breast Carcinoma Malignancy Through the SFRP1/ Wnt/β-catenin Signaling Axis

Downregulation of microRNA‐326 enhances ZNF322A expression, transcriptional activity and tumorigenic effects in lung cancer

Zinc-finger Protein 382 Antagonises CDC25A and ZEB1 Signaling Pathway in Breast Cancer

ZMIZ2 promotes the development of triple-receptor negative breast cancer

The transcription factor ZNF248 promotes colorectal cancer metastasis by binding to ZEB1

ZNF746 promotes M2 macrophage polarisation and favours tumour progression in breast cancer via the Jagged1/Notch pathway

ZNF133 is a potent suppressor in breast carcinogenesis through dampening L1CAM, a driver for tumor cell invasion

ZNF133 is a Potent Suppressor in Breast Carcinogenesis Through Dampening L1CAM, a Driver for Tumor Progression

ZFHX3 Promotes the Proliferation and Tumor Growth of ER-Positive Breast Cancer Cells Likely by Enhancing Stem-Like Features and MYC and TBX3 Transcription

ZNF703 promotes triple-negative breast cancer cells through cell-cycle signaling and associated with poor prognosis

ZNF121 interacts with ZBRK1 and BRCA1 to regulate their target genes in mammary epithelial cells.

Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells

Zinc finger protein 468 up-regulation of TFAM contributes to the malignant growth and cisplatin resistance of breast cancer cells

53BP1 suppresses epithelial–mesenchymal transition by downregulating ZEB1 through microRNA‐200b/429 in breast cancer